天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ChemicalBook >> journal list >> Drugs >>article
Drugs

Drugs

IF: 13
Download PDF

Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension.

Published:1 May 1996 DOI: 10.2165/00003495-199651050-00008 PMID: 8861549
K L Goa, A J Wagstaff

Abstract

Losartan potassium is an orally active, nonpeptide angiotensin II (AII) receptor antagonist. It is the first of a new class of drugs to be introduced for clinical use in hypertension. This novel agent binds competitively and selectively to the AII subtype 1 (AT(1)) receptor, thereby blocking AII-induced physiological effects. An active metabolite, E3174, contributes substantially to its antihypertensive effect, which persists throughout 24 hours after once-daily administration. In patients with mild to moderate hypertension, losartan potassium 50 to 100mg once daily as monotherapy lowers blood pressure to a similar degree to enalapril, atenolol and felodipine extended release (ER). Losartan potassium combined with hydrochlorothiazide reduces blood pressure further than either drug given separately. About one-third of patients with severe hypertension have responded to the combination product. Losartan potassium appears to be effective in elderly patients. Losartan potassium is very well tolerated. In clinical trials, dizziness was the only drug-related event reported more frequently with losartan potassium monotherapy than with placebo. First-dose hypotension is uncommon. An aspect of the drug's tolerability profile which may prove to be particularly advantageous is that it is associated with a similar incidence of cough to placebo in patients with a history of ACE inhibitor-related cough. Additionally, clinically relevant adverse metabolic effects or laboratory abnormalities have not been documented during losartan potassium therapy and renal function is preserved in patients with or without renal insufficiency. The adverse effect profile of the losartan potassium-hydrochlorothiazide combination resembles those for losartan potassium monotherapy and placebo. Long term tolerability data are limited (<2 years) but support the very good tolerability profile in shorter studies. Elements of the drug's profile yet to be assessed or reported fully in the literature include long term efficacy; potential to favourably influence cardiovascular and renovascular systems (and ultimately mortality) in patients with hypertension and, lastly, cost effectiveness and influence on quality of life. In summary, losartan potassium is the first AT(1)+ receptor antagonist to become available for the management of hypertension and, as such, it is an important new antihypertensive agent. Pending long term data as outlined above, it is likely to find initial use in patients with mild to severe hypertension who are unresponsive to, or intolerant of their current therapy. However, with its novel mechanism of action, good efficacy and favourable tolerability profile, losartan potassium is well placed to claim a prominent position in the management of patients with essential hypertension in the future.

Substances (7)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Losartan potassium 124750-99-8 C22H23ClKN6O 849 suppliers $5.00-$541.00
Hydrochlorothiazide 58-93-5 C7H8ClN3O4S2 593 suppliers $14.00-$1950.00
Atenolol 29122-68-7 C14H22N2O3 383 suppliers $15.00-$1400.00
Felodipine 86189-69-7 C18H19Cl2NO4 202 suppliers Inquiry
Enalapril 75847-73-3 C20H28N2O5 193 suppliers $30.00-$1500.00
Losartan carboxylic acid 124750-92-1 C22H21ClN6O2 165 suppliers $7.00-$1750.00
Losartan potassium 12475-99-8 C22H22ClKN6O 23 suppliers Inquiry

Similar articles

IF:2.4

Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability.

Current Medical Research and Opinion Jonathan A Bernstein,etc Published: 1 October 2007
IF:6.1

Andrographolide: A review of its pharmacology, pharmacokinetics, toxicity and clinical trials and pharmaceutical researches.

Phytotherapy Research Bin Zeng, Ailing Wei,etc Published: 1 January 2022
IF:13

Dutasteride: a review of its use in the management of prostate disorders.

Drugs Susan J Keam, Lesley J Scott,etc Published: 1 January 2008